Gain Therapeutics, Inc.
Qualité des données : 83%
GANX
NASDAQ
Manufacturing
Chemicals
2,05 €
▼
0,09 €
(-4,21%)
6 months return
—
Momentum
Neutral
ROE
-419,78%
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-419,78%
En dessous de la moyenne du secteur (-54,47%)
ROIC-258,46%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,07
En dessous de la moyenne du secteur (0,30)
Current Ratio2,52
Interest CoverageN/A
Valorisation
PE (TTM|NTM)
-3,89 | -3,43
En dessous de la moyenne du secteur (-1,50)
P/B Ratio13,27
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -18,47 M
Price History
Tendances Financières
Objectif de Cours des Analystes
5 analystes
Buy
+270.7%
upside to target
Actuel
2,05 €
Consensus Target
7,60 €
5,00 €
Bas
10,00 €
Haut
Prévisions
P/E Prévisionnel
-3,43
BPA Prévisionnel
-0,62 €
CA Est.
0,0
Surprises de Résultats
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -0,14 €
·
Rev Est: 0,0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -0,16 € | -0,19 € | -0,15 € | -0,11 € | — | — |
| Estimate | -0,17 € | -0,17 € | -0,15 € | -0,15 € | -0,14 € | -0,15 € |
| Surprise | +4,00% | -11,76% | +2,17% | +24,14% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -419,78% · Net Margin: N/A
Profitability
ROE: -419,78% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -20,16 M |
| ROE | -419,78% | ROA | -193,80% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -18,47 M |
| ROIC | -258,46% | FCF Growth (3Y) | N/A |
Safety
D/E: 0,07 · Current: 2,52
Safety
D/E: 0,07 · Current: 2,52| Debt / Equity | 0,07 | Current Ratio | 2,52 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 6,35 M | Tangible Book Value | 5,91 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -3,89 · EV/EBITDA: N/A
Valuation
P/E: -3,89 · EV/EBITDA: N/A| P/E Ratio | -3,89 | Forward P/E | -3,43 |
| P/B Ratio | 13,27 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -23,56% | ||
| Market Cap | 78,39 M | Enterprise Value | 70,01 M |
Per Share
EPS: -0,61 · FCF/Share: -0,43
Per Share
EPS: -0,61 · FCF/Share: -0,43| EPS (Diluted TTM) | -0,61 | Revenue / Share | N/A |
| FCF / Share | -0,43 | OCF / Share | -0,43 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 91,59% · CapEx/Rev: N/A
Efficiency
FCF Conv: 91,59% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 91,59% |
| SBC-Adj. FCF | -20,22 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 55 180,0 | 55 180,0 | 140 108,0 | 164 994,0 |
| Net Income | -20,16 M | -20,41 M | -22,27 M | -17,59 M | -13,89 M |
| EPS (Diluted) | -0,61 | -0,89 | -1,71 | -1,48 | -1,37 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -18,71 M | -20,35 M | -22,25 M | -17,78 M | -13,83 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 10,21 M | 10,79 M | 11,52 M | 8,38 M | 7,16 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 94 046,0 | 84 071,0 | 83 579,0 | 64 168,0 | 15 484,0 |
| Interest Expense | — | — | 494 234,0 | 375 357,0 | 0,0 |
| Income Tax | 861 118,0 | 536 815,0 | 79 275,0 | 92 976,0 | 4 008,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22,82 M | 12,12 M | 18,61 M | 24,10 M | 38,99 M |
| Total Liabilities | 4,25 M | 4,78 M | 6,03 M | 5,22 M | 4,17 M |
| Shareholders' Equity | 18,56 M | 7,34 M | 12,58 M | 18,88 M | 34,82 M |
| Total Debt | 400 953,0 | 438 504,0 | 567 850,0 | 603 393,0 | 694 294,0 |
| Cash & Equivalents | 20,84 M | 10,39 M | 11,79 M | 7,31 M | 36,88 M |
| Current Assets | 22,24 M | 11,60 M | 17,78 M | 21,09 M | 37,72 M |
| Current Liabilities | 3,35 M | 3,91 M | 4,95 M | 4,13 M | 2,55 M |
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs)
Par rapport à des entreprises similaires dans Manufacturing
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs) Par rapport à des entreprises similaires dans Manufacturing| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -3,9 | -1,5 |
| P/B | 13,3 | 1,6 |
| ROE % | -419,8 | -54,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | 0,1 | 0,3 |
ETFs Holding This Stock
ETFs Holding This Stock
BRSIX
BRSIX
0,06% weight
{"event":"ticker_viewed","properties":{"ticker":"GANX","listing_kind":"stock","pathname":"/stocks/ganx","exchange":"NASDAQ","country":"US"}}